Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658968 | 0.91 | POLB (0.57) | POLBGAASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL6664203 | 0.90 | MAPT (0.40) | POLBGAASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL6661473 | 0.88 | MAPT (0.54) | POLBGAASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6662943 | 0.84 | POLB (0.50) | POLBGAASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL6660590 | 0.82 | POLB (0.48) | POLBGAASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL6660442 | 0.76 | GAA (0.42) | POLBGAASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6666199 | 0.75 | MAPT (0.42) | POLBSMN1; SMN2CYP1A2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL6660111 | 0.75 | GAA (0.41) | POLBGAASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6661847 | 0.71 | MAOA (0.38) | POLBGAASMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL6661440 | 0.71 | SMN1; SMN2 (0.47) | POLBSMN1; SMN2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268436-B1 | NOVEL DIAMINOPYRAZOLE DERIVATIVES AND DYES CONTAINING SAID COMPOUNDS | WELLA AG (DE) | 2004-08-18 | — | — | EP | disclosed |
| US-6600050-B2 | Inorganic and organic acids and agents, containing these compounds, for the oxidative dyeing of fibers such as hair for hair dyes | WELLA AG (DE) | 2003-07-29 | — | — | US | disclosed |
| US-20030115684-A1 | Novel diaminopyrazole derivatives and dyes containing said compounds | HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) | 2003-06-26 | — | — | US | disclosed |
| EP-1268436-A1 | NOVEL DIAMINOPYRAZOLE DERIVATIVES AND DYES CONTAINING SAID COMPOUNDS | Wella Aktiengesellschaft (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002072556-A1 | NOVEL DIAMINOPYRAZOLE DERIVATIVES AND DYES CONTAINING SAID COMPOUNDS | WELLA AKTIENGESELLSCHAFT (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030115684-A1 | Novel diaminopyrazole derivatives and dyes containing said compounds | AOC1, DPYD, PPOX | POLB 361/4885GAA 1099/4885SMN1; SMN2 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.